PDCD1 and non-small cell lung carcinoma: In this retrospective study, we fully evaluated the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy in the second or later-line treatment of patients with advanced non-small cell lung cancer.